A Study of TQB3454 Tablets in Patients With Blood Tumors
The purpose of this clinical trial is to evaluate the safety of TQB3454 tablets in patients with acute myeloid leukemia and myelodysplastic syndrome, and determine the phase II recommended dose.
Acute Myeloid Leukemia|Myelodysplastic Syndromes
DRUG: TQB3454 Tablets
The rate of all adverse events (AEs), serious adverse events (SAEs), Proportion of patients with adverse events/serious adverse events, as defined by Common Terminology Criteria for Adverse Events (CTCAE5.0), Up to 80 weeks|The severity of all adverse events (AEs), serious adverse events (SAEs), The severity of adverse events/serious adverse events, as defined by Common Terminology Criteria for Adverse Events (CTCAE5.0), Up to 80 weeks|Incidence of abnormal laboratory values, The proportion of patients with abnormal laboratory examination indicators mainly included blood routine, blood routine, blood biochemistry, coagulation function, thyroid function, myocardial enzyme profile, urine routine, stool routine and 12-lead electrocardiogram., Up to 80 weeks
Peak time (Tmax), The time required to reach peak concentration after administration., Cohort 1: pre-dose on Day 1, 14, 28 of Cycle 1, Day 14, 28 of Cycle 2. 2, 3, 4, 10, 24 hours after dose on Cycle1 Day28. Cohort 2: pre-dose, 2, 3, 4, 10, 24 hours after dose on Day 1, 28 of Cycle 1. Pre-dose on Day 14, 28 of Cycle2. 28 days as a cycle.|Peak concentration (Cmax), the maximum plasma concentration of the drug after administration., Cohort 1: pre-dose on Day 1, 14, 28 of Cycle 1, Day 14, 28 of Cycle 2. 2, 3, 4, 10, 24 hours after dose on Cycle1 Day28. Cohort 2: pre-dose, 2, 3, 4, 10, 24 hours after dose on Day 1, 28 of Cycle 1. Pre-dose on Day 14, 28 of Cycle2. 28 days as a cycle.|Area under blood concentration-time curve (AUC 0-24h), The area surrounded by the blood concentration curve to the time axis., Cohort 1: pre-dose on Day 1, 14, 28 of Cycle 1, Day 14, 28 of Cycle 2. 2, 3, 4, 10, 24 hours after dose on Cycle1 Day28. Cohort 2: pre-dose, 2, 3, 4, 10, 24 hours after dose on Day 1, 28 of Cycle 1. Pre-dose on Day 14, 28 of Cycle2. 28 days as a cycle.|Steady-state apparent volume of distribution (Vz/F), The volume of distribution at steady-state concentration., Cohort 1: pre-dose on Day 1, 14, 28 of Cycle 1, Day 14, 28 of Cycle 2. 2, 3, 4, 10, 24 hours after dose on Cycle1 Day28. Cohort 2: pre-dose, 2, 3, 4, 10, 24 hours after dose on Day 1, 28 of Cycle 1. Pre-dose on Day 14, 28 of Cycle2. 28 days as a cycle.|Steady-state blood trough concentration (Cmin,ss), the lowest concentration during dosing and is usually obtained from the initial moment after dosing to the lowest concentration before the next dosing when multiple dosing reaches steady-state., Cohort 1: pre-dose on Day 1, 14, 28 of Cycle 1, Day 14, 28 of Cycle 2. 2, 3, 4, 10, 24 hours after dose on Cycle1 Day28. Cohort 2: pre-dose, 2, 3, 4, 10, 24 hours after dose on Day 1, 28 of Cycle 1. Pre-dose on Day 14, 28 of Cycle2. 28 days as a cycle.|Complete response (CR) rate, The proportion of patients with an optimal response of CR., Up to 80 weeks|Complete response (CR) + Complete response with partial hematological recovery (CRh), Proportion of patients with optimal response of CR and CRh, Up to 80 weeks|Transfusion-independent improvement, Proportion of transfusion-dependent patients at baseline who were removed from red blood cell (RBC) or platelet transfusion dependence after randomization., Up to 80 weeks|CR+CRh duration, In all patients with an optimal response of CR or CRh, the time from the date when CR or CRh was first achieved to the date of first clearly documented disease progression / relapse / treatment failure or death, whichever occurs first., Up to 80 weeks|CR duration, For all patients with an optimal response of CR, the time from the date when CR was first achieved to the first clearly documented date of disease progression/relapse/treatment failure or death, whichever occurs first., Up to 80 weeks|Duration of response (DOR), The time from the date of first remission to the date of first clearly documented disease progression/relapse/treatment failure or date of death in all patients with optimal response of CR, CR with incomplete blood count recovery(CRi), CR with incomplete platelet recovery (CRp), Morphologic Leukemia-free state (MLFS), or Partial Remission (PR), whichever occurs first., Up to 80 weeks|Time to CR+CRh, Time from the date of first TQB3454 dose to the date of first CR or CRh in all patients with optimal response to CR or CRh., Up to 80 weeks|Event-free survival (EFS), The time from the date of the first dose TQB3454 tablet to the first clearly documented date of relapse after disease remission, disease progression/treatment failure, or death, whichever occurs first., Up to 80 weeks|Overall survival (OS), Time from the date of first dose of TQB3454 tablet to the date of death from any cause., Up to 80 weeks|Functional Assessment of Chronic Illness (FACIT) fatigue Scale, Proportion of patients with a confirmed improvement of at least 3 points from baseline in FACit-Fatigue scale scores., Up to 80 weeks|Quality of life score, Proportion of patients with a confirmed improvement of at least 10 points from baseline in their overall health as assessed by European organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)., Up to 80 weeks|Overall response rate (ORR), Proportion of patients with an optimal response of CR, marrow CR (mCR), PR, or Hematology improvement (HI)., Up to 80 weeks|Progression-free survival (PFS), from the date of first dose of TQB3454 tablet to the time of first recorded disease progression assessed by the investigator or relapse after CR or death from any cause. Disease progression includes acute leukaemia transformation., Up to 80 weeks|Leukemia-free survival, from the date of first dose of TQB3454 tablet to the time of \>20% original cells in bone marrow/peripheral blood, or diagnosis of acute extramedullary leukemia, or death from any cause., Up to 80 weeks|Correlation between 2-hydroxyglutaric acid (2-HG) and efficacy, Liquid chromatography-mass spectrometry (LC-MS/MS) was used to determine 2-HG in plasma and to analyze its correlation with efficacy., Pre-dose (baseline). Pre-dose on Cycle 1 Day 14, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, Cycle 4 Day 28, Cycle 5 Day 28, Cycle 6 Day 28, 28 days as a cycle
The purpose of this clinical trial is to evaluate the safety of TQB3454 tablets in patients with acute myeloid leukemia and myelodysplastic syndrome, and determine the phase II recommended dose.